14 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16420030	38	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.	Chinese Academy of Sciences
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy of Sciences
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals